García HY

Language: Spanish
References: 8
Page: 292-300
PDF size: 439.28 Kb.

ABSTRACT

Rationale: CombiFer^® (BioCen, Mayabeque, Cuba) is a nutritional supplement used for the prevention of anemia in pregnant women offered as tablets, and containing dehydrated Trofin (BioCen, Mayabeque, Cuba): 300 mg; Ascorbic acid (AA): 60 mg; Ferrous fumarate (FF): 50 mg; and folic acid (FA): 0.24 mg. It was of interest to have an analytical for quantitating the FA present in the tablet. Objective: To assess a high performance liquid chromatography (HPLC) application used for quantitating the FA content of the tablet. Material and method: A quantity of CombiFer^® powder equivalent to the average weight of a Tablet was weighted, dissolved in distilled water, allowed to precipitate by gravity, and redissolved in distillied water. Three solubilizationprecipitation by gravity-resolubilization cycles were completed. The resulting precipitate (containing FA + FF) was dissolved by ultrasound in a NaClO₄ (7.5 g.L^-1) + K₂HPO₄ (0.6 g.L^-1) + Methanol (135 mL) mix at pH 7.2 during 3 minutes. Samples were assayed with the HPLC application using a C18 reverse-phase column. A NaClO₄ (9.4 g.L^-1) + K₂HPO₄ (0.75 g.L^-1) mix (pH 7.2) at 1 mL.minute^-1 flow rate was used as mobile phase. Eluates were detected at 277 nm. Under the same conditions references samples of FA, FF, dehydrated Trofin and AA were also assayed. Results: FF interfered in the quantitation of FA, resulting in low FA contents in the three assayed lots: Lot #3001: 0.034 ± 0.002 mg.tablet^-1 (Recovery: 14.25%); Lot #2: 0.055 ± 0.001 mg.tablet^-1 (22.85%); and Lot #3003: 0.044 ± 0.001 mg.tablet^-1 (18.59%). It is believed observed results are caused by the acid pH of the milieu in which FA is separated, thus favoring oxidation of the molecule. Conclusions: Under used experimental conditions the assessed HPLC application does not allow the quantitation of FA.

REFERENCES

1. Sant-Rayn P, Drakesmith H, Black J, Hipgrave D, Berveley-Ann B. Control of iron deficiency anemia in low-and middle-income countries. Blood 2013; 121:2607-17.

2. Pita GM, Jiménez S, Basabe B, García RG, Macías C, Selva L; et al. Anemia in children under five years old in Eastern Cuba, 2005-2011. MEDICC Review 2014;16:16-23.

3. Kassebaum NJ, Jasrasaria R, Lozano R, Eisele TP, Brooker SJ, Naghavi M; et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014; 123:615-24.

4. Aznar E, González R, González M, Suárez S. Utilización del Trofin, NeoTrofin y sus formulaciones con vitamina C y ácido fólico para disminuir la anemia por deficiencia de hierro. En: Alimentación, nutrición y salud. INHA Instituto de Nutrición e Higiene de los Alimentos. La Habana: 2002. pp 173-75.

5. British Farmacopoeia 2013. Folic acid and ferrous fumarate tablets. Volume III. Seven Edition. United Kingdom: 2012. pp 101.

6. Marchante PH, Zumbado A, González M, Alvarez M, Hernández L. Análisis químico farmacéutico. Métodos clásicos cuantitativos. Universidad de la Habana. La Habana: 2008. Pp 297.

7. Yakubu S, Muazu J. Effects of variables on degradation of folic acid. Der Pharmacia Sinica 2010;1:55-8.

8. González R, Aznar E, Achong A [Inventores]. Hemoderivado en polvo para la profilaxis y tratamiento de la deficiencia de hierro. OCPI Oficina Cubana de la Propiedad Industrial. La Habana: 2000. Número de registro: CU 22599 A1.